Clinical Overview

Atopic dermatitis (eczema) affects 10-20% of children, making it the most common chronic inflammatory skin disease in pediatric populations. This chronic condition is characterized by intense pruritus, xerosis (dry skin), and reactive hypersensitivity to irritants and allergens. Early-onset disease frequently correlates with more severe phenotypes and increased risk of associated allergic conditions. Evidence-based management focused on skin barrier repair and anti-inflammatory therapy significantly improves quality of life and reduces disease burden.

Epidemiology

Atopic dermatitis affects 10-20% of children globally, with higher prevalence in developed countries. Peak onset occurs before age 5 years, though it may persist or develop later. Female predominance emerges after puberty. Family history is present in 60-70% of affected children. Associated atopic conditions (allergic rhinitis, asthma, food allergy) occur in 30-50% of children with AD. Early-onset disease and moderate-to-severe phenotypes predict persistence into adulthood.

Pathophysiology

Atopic dermatitis results from complex interactions between impaired skin barrier function, immune dysregulation, and genetic predisposition. Filaggrin gene mutations impair barrier function, allowing increased transepidermal water loss and allergen penetration. Dysregulated Th2-predominant immune response with elevated IgE and IL-4, IL-5, IL-13 leads to inflammation. Scratching and dysfunction of antimicrobial peptides increase Staphylococcus aureus colonization. Genetic variations in tight junction proteins and lipid metabolism further compromise barrier integrity.

Clinical Presentation

Affected children present with intense pruritus (often worse at night), visible xerosis, and lichenified patches from chronic scratching. Acute flares show erythema, vesicles, and exudation. Chronic lesions appear lichenified and hyperpigmented. Typical distribution includes face and extremities in infants, flexural surfaces (antecubital and popliteal fossae) in older children. Facial eczema and hand dermatitis are common in school-age children. Visible scratching damage often indicates disease severity.

Diagnosis

Clinical diagnosis is based on Hanifin and Rajka criteria: pruritus, typical morphology and distribution, chronic or relapsing course, and personal history of atopy. Elevated serum IgE (50-80% of patients) and IgE specific to environmental allergens support diagnosis. RAST or skin prick testing may identify relevant allergen triggers. Patch testing helps identify allergic contact dermatitis component. Biopsy is rarely needed but shows spongiosis and perivascular lymphocytic infiltrate.

Treatment (Age-Specific)

Infants (0-12 months): Emollient therapy is cornerstone: apply thick creams or ointments (cetaphil, eucerin, aquaphor) within 3 minutes of bathing. Bathing frequency: daily 5-10 minute warm baths (not hot). Mild cleansers (cetaphil, aveeno) are preferred. For active inflammation, topical hydrocortisone 1% cream twice daily (maximum 30 g/week on body, 10 g/week on face). Tacrolimus 0.03% ointment twice daily offers steroid-sparing benefits for sensitive areas.

Toddlers (1-3 years): Continue intensive emollient use. Active disease: triamcinolone acetonide 0.1% cream twice daily (maximum 50 g/week). Tacrolimus 0.03% ointment for facial/intertriginous involvement. Topical calcineurin inhibitors reduce risk of atrophy compared to prolonged steroid use. Avoid irritants and known allergen triggers. Consider allergen testing if disease is difficult to control.

School-Age (6-12 years): Emollient therapy remains essential: apply immediately after bathing. Topical corticosteroids (fluticasone propionate 0.005% cream twice daily, or triamcinolone 0.1% ointment for body) for active disease. Topical calcineurin inhibitors for face and skin folds. Phototherapy (NB-UVB 311 nm, 2-3 times weekly) for generalized disease refractory to topical therapy. Antihistamines at night (cetirizine 2.5-5 mg, loratadine 2-5 mg) may help with sleep disruption.

Adolescents (12+ years): Systemic therapy options for moderate-to-severe disease: oral cyclosporine 3-5 mg/kg/day, or dupilumab (monoclonal antibody) 300-400 mg weekly (for age 12+). Azathioprine 1-3 mg/kg/day and mycophenolate mofetil 20-40 mg/kg/day are alternatives. Phototherapy: NB-UVB or PUVA (psoralen + UVA). Continue emollient and topical therapy as foundation.

Procedural details: NB-UVB: 311 nm, dose 0.2-0.5 J/cm² initially, increase 5-10% each session. Dupilumab: 400 mg initial dose, then 200 mg weekly (halve doses for children 15-30 kg). Cyclosporine monitoring: baseline renal function, blood pressure, drug levels; repeat every 4 weeks.

Prognosis

Approximately 60% of children with childhood-onset atopic dermatitis clear by adulthood, while 40% have persistence or recurrence. Early-onset, severe disease, and family history predict persistent disease. Early intervention and proactive skin care improve outcomes. Most children achieve substantial improvement in quality of life with appropriate management. Adult-onset disease has worse prognosis for complete resolution.

When to See a Pediatric Dermatologist

Referral is appropriate for moderate-to-severe disease, disease not responding to standard topical therapy, complicated flares with secondary infection, or consideration of systemic therapy. Dermatologists guide treatment selection, monitor for adverse effects of systemic agents, and provide specialized phototherapy. Early specialist involvement optimizes long-term outcomes.

FAQ

Q: Is eczema contagious?
A: No, atopic dermatitis is not contagious. It is an inherited inflammatory skin condition caused by genetic predisposition and environmental factors, not infection. Your child cannot spread it to other people through contact, skin-to-skin transmission, or sharing items.

Q: What triggers my child's eczema flares?
A: Common triggers include dry skin, irritants (harsh soaps, detergents), allergens, stress, heat/sweating, and infections. Identifying specific triggers through careful observation helps prevent flares. Keeping a diary of flares and potential triggers can help identify patterns specific to your child.

Q: How often should I bathe my child with eczema?
A: Daily baths of 5-10 minutes in warm (not hot) water with mild soap are recommended. Immediate application of thick emollients (creams or ointments) within 3 minutes of bathing seals moisture into the skin. Frequent, short baths with prompt emollification is more effective than less frequent bathing.

Q: Are topical steroids safe for my child?
A: Yes, when used appropriately. Low-potency steroids (hydrocortisone 1%) on face, and mid-potency steroids (triamcinolone 0.1%) on body are safe for children with eczema. Long-term use can cause skin atrophy, so combining with non-steroidal agents (tacrolimus) and emollients is recommended. Your dermatologist can guide safe usage.

References

  1. Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis. J Am Acad Dermatol. 2014;71(1):116-132.
  2. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol Suppl. 1980;92:44-47.
  3. Leung DYM, Boguniewicz M, Howell MD, et al. New insights into atopic dermatitis. J Clin Invest. 2004;113(5):651-657.
  4. Palmer CN, Irvine AD, Terron-Kwiatkowski A, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet. 2006;38(4):441-446.
  5. Ong PY, Ohtake T, Yang C, et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med. 2002;347(15):1151-1160.
  6. Boguniewicz M, Leung DYM. Atopic dermatitis: a disease of altered skin barrier and immune dysregulation. Immunol Rev. 2011;242(1):233-246.
  7. Paller AS, Kong HH, Seed P, et al. The microbiome in patients with atopic dermatitis. J Allergy Clin Immunol. 2016;139(3):915-921.
  8. De Benedetto A, Agnihothri R, McGirt LY, et al. Atopic dermatitis. Clin Dermatol. 2011;29(1):34-40.
  9. Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335-2348.
  10. Sampson HA, Akdis CA, Bock SA, et al. Mechanisms of food allergy. J Allergy Clin Immunol. 2018;141(1):11-19.